Question Bank › Skeptical premise dismantled with receipts

Skeptical premise dismantled with receipts

Skeptical premise dismantled with receipts: the call's central doubt is answered by named, checkable current facts

Calls Tested

497

Answered YES

Hit Rate

4.8%

rare by design

Agios Pharmaceuticals, Inc. (AGIO) — this company's answers

NO on the Q3 2018 call 2018-11-01 C

The model's full reasoning — Q3 2018 call → NOWe need to determine if there is a specific doubt about the company that is live in the conversation, and whether management answers that doubt with named, checkable facts from the recent period that run directly against it. The doubt must be company-specific, and the rebuttal must be concrete, already-realized operating facts. Looking at the transcript, there are several topics: TIBSOVO launch, clinical trials, financials. The analysts ask about duration of therapy, testing rates, etc. But is there a specific doubt? Possibly about the launch trajectory, or about the ability to compete, or about the AG-270 program. However, the question asks for a "doubt about this company" that is "live in the conversation" and that management answers with "named, checkable facts from the recent period" that run directly against it. One candidate: The doubt about TIBSOVO's launch performance relative to IDHIFA. Analysts ask about duration, trajectory. Management responds with facts: net sales of $4.5 million, over 100 unique prescribers, awareness above 90%, testing rates at 80%. These are checkable facts. But is there a specific doubt? The analysts are not expressing a doubt; they are asking for updates. The management is providing positive data. There's no explicit doubt being raised. Another candidate: The doubt about the AG-270 program. Analyst asks if lack of anti-cancer activity means something. Management says don't infer, we'll present later. That's not a rebuttal with facts. Another: The doubt about the frontline AML strategy. Management announces acceleration and sNDA. That's not a doubt. Perhaps the doubt is about the company's ability to sustain growth after CEO transition? But that's not addressed with facts. The question asks: "Is there ONE IDENTIFIABLE DOUBT ABOUT THIS COMPANY THAT IS LIVE IN THE CONVERSATION — evident because analysts press it, or because management itself names it as what skeptics or the market believe — AND does management answer that specific doubt NOT with reassurance, plans, or argument, but with NAMED, CHECKABLE FACTS FROM THE RECENT PERIOD that run directly against it?" Looking for a doubt that is pressed. Analysts ask about duration, but that's not a doubt, it's a question. They ask about testing rates, but that's not a doubt. They ask about AG-270, but management deflects.

← Back to the full AGIO analysis

Show the exact prompt the model was given

Using ONLY the supplied earnings call transcript and no outside information: On this call, is there ONE IDENTIFIABLE DOUBT ABOUT THIS COMPANY THAT IS LIVE IN THE CONVERSATION — evident because analysts press it, or because management itself names it as what skeptics or the market believe — AND does management answer that specific doubt NOT with reassurance, plans, or argument, but with NAMED, CHECKABLE FACTS FROM THE RECENT PERIOD that run directly against it — concrete events, behaviors, or numbers already realized (customers renewed or expanded when expected to leave, demand that held or grew through the feared window, losses that narrowed from operations, the doubted product performing in real use, the feared dependency reduced by actual new business) — described specifically enough that a reader could later verify them, with management conveying that the same contrary evidence is continuing rather than a one-quarter fluke? Answer YES when both halves come through as one dynamic in the transcript, in whatever form fits the business: a genuine, company-specific standing doubt, and a rebuttal built from already-occurred operating facts that the doubt's holders could check. It strengthens a YES when management engages the doubt directly and calmly rather than deflecting, and when the facts offered are of a kind that will keep accruing. Answer NO if no company-specific doubt is visible — an ordinary healthy company fielding routine questions. NO if the doubt exists but the answer is chiefly confidence, vision, targets, or projections. NO if the period's evidence actually confirms the doubt and management is excusing it. NO if the contrary facts are one-time items (asset sales, settlements, financings) rather than operating substance. NO if the doubt is generic macro gloom not attached to this company. NO if the rebuttal facts are vague ('demand remains strong') without specific grounding. NO if the dynamic appears only in an analyst's characterization that management does not itself engage with substance. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

Ticker	Company	Call	Date	Call grade
GL	Globe Life Inc.	Q1 2024	2024-04-23	F
MET	MetLife, Inc.	Q4 2023	2024-02-01	B+
SITM	SiTime Corporation	Q2 2023	2023-08-02	C+
PGRE	Paramount Group, Inc.	Q2 2023	2023-08-01	D
MBLY	Mobileye Global Inc.	Q2 2023	2023-07-28	B+
CRBG	Corebridge Financial, Inc.	Q4 2022	2023-02-22	B
UAL	United Airlines Holdings, Inc.	Q4 2022	2023-01-18	B
CRL	Charles River Laboratories International	Q2 2022	2022-08-03	C
LIN	Linde plc	Q2 2022	2022-07-28	B+
CME	CME Group Inc.	Q2 2022	2022-07-27	B
BFIN	BankFinancial Corporation	Q1 2022	2022-05-06	A
BXP	Boston Properties, Inc.	Q1 2022	2022-05-03	A
VVV	Valvoline Inc.	Q1 2022	2022-02-09	C+
IPGP	IPG Photonics Corporation	Q3 2021	2021-11-02	C
AMC	AMC Entertainment Holdings, Inc.	Q2 2021	2021-08-09	D
ESRT	Empire State Realty Trust, Inc.	Q2 2021	2021-07-29	C+
T	AT&T Inc.	Q3 2018	2018-10-24	C+
AVT	Avnet, Inc.	Q2 2018	2018-01-25	B
PII	Polaris Inc.	Q3 2017	2017-10-24	C+
GNTX	Gentex Corporation	Q3 2017	2017-10-20	B
CCOI	Cogent Communications Holdings, Inc.	Q2 2017	2017-08-03	B
TGI	Triumph Group, Inc.	Q2 2017	2016-11-03	C+
HPP	Hudson Pacific Properties, Inc.	Q4 2015	2016-02-25	C
SAN	Banco Santander, S.A.	Q4 2015	2016-01-27	B

How the model reasoned

IPGP · Q3 2021 → YESThe question is very specific: Is there ONE IDENTIFIABLE DOUBT ABOUT THIS COMPANY THAT IS LIVE IN THE CONVERSATION, and does management answer it with NAMED, CHECKABLE FACTS FROM THE RECENT PERIOD tha...YES The transcript shows a clear, company-specific doubt centered on China market softness and competitive pricing pressure, which analysts repeatedly press (e.g., on whether gross margins will hold, if diversification will offset the impact, and whether LightWELD can scale). Management directly engages this doubt by citing concrete, checkable facts from 2022: China revenue down only 7% while North America grew +55% and Europe +50%, gross margin expanded 100 bps to 49% driven by product mix and pricing discipline, and other China applications (EV battery, additive manufacturing, marking) remained robust.

CRBG · Q4 2022 → YESThe question is very specific: Is there ONE IDENTIFIABLE DOUBT ABOUT THIS COMPANY THAT IS LIVE IN THE CONVERSATION, and does management answer it with NAMED, CHECKABLE FACTS FROM THE RECENT PERIOD tha...YES The transcript shows a clear, company-specific doubt about elevated fixed annuity surrenders in a rising-rate environment, which analysts press and management itself flags as expected for 2023.

GL · Q1 2024 → YESThe question is: Is there ONE IDENTIFIABLE DOUBT ABOUT THIS COMPANY THAT IS LIVE IN THE CONVERSATION, and does management answer that specific doubt with NAMED, CHECKABLE FACTS FROM THE RECENT PERIOD ...

Skeptical premise dismantled with receipts

Agios Pharmaceuticals, Inc. (AGIO) — this company's answers

Companies that answered YES

How the model reasoned

More from the question bank